Evaluation of programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) as tumor biomarkers an in patients with head and neck squamous cell carcinoma

DOI: 10.18044/Medinform.202072.1198

Abstract:

The use of onco-biomarkers such as programmed death 1 (PD-1) and its ligand, PD-L1, present a new opportunity for the diagnosis and treatment of head and neck squamous cell carcinomas (HNSCC). These molecules modulate the immune response of the host and aid the tumor cells to escape immune surveillance. The overexpression of PD-1/PD-L1 in some HNSCC is a predictive biomarker to the response of checkpoint inhibitor immunotherapeutic drugs.

Authors:

Elitsa Deliverska; Department of Dental, Oral and Maxillofacial surgery, Faculty of Dental Medicine, Medical University of Sofia;
Payam Forghani; Student in Faculty of Dental Medicine, Medical University of Sofia;
Sadeta Parusheva; Department of Dental, Oral and Maxillofacial surgery, Faculty of Dental Medicine, Medical University of Sofia;

Corresponding Author:

Elitsa Deliverska; Faculty of Dental Medicine, Medical University of Sofia, Department of Dental, Oral and Maxillofacial Surgery; Sofia 1431 Str. Georgi Sofiiski 1;